A roundup of news from Jazz Pharmaceuticals/Chimerix, Genentech/Repertoire, Galapagos, and Asahi Kasei. Highlights below.  

M&A News 
* Jazz Pharmaceuticals Completes $935-M Acquisition of Chimerix 
Partnering News 
* Genentech, Repertoire in $765-M Autoimmune Disease Drug Pact 
Appointments 
* Galapagos Appoints CEO of Subsidiary, Announces Search for CEO of Galapagos 
* Asahi Kasei Names Head of Healthcare Sector 

---

M&A News 

Jazz Pharmaceuticals Complètes $935-M Acquisition of Chimerix 
Jazz Pharmaceuticals, a Dublin, Ireland-based bio/pharmaceutical company, has completed its $935-million acquisition of Chimerix, a Durham, North Carolina-based bio/pharmaceutical company. Chimerix is now a wholly owned subsidiary of Jazz Pharmaceuticals.  

The acquisition includes the addition of dordaviprone, an investigational small-molecule drug for treating H3 K27M-mutant diffuse glioma, a rare, aggressive, and invasive brain cancer, primarily affecting children and young adults. Dordaviprone is currently under priority review by the US Food and Drug Administration (FDA), with a Prescription Drug User Fee Act (PDUFA) action date set for August 18, 2025. If approved in the US, the therapy may be eligible for a Rare Pediatric Disease Priority Review Voucher. Dordaviprone is also being studied in an ongoing Phase III  trial to evaluate its use in newly diagnosed, non-recurrent H3 K27M-mutant diffuse glioma patients following radiation treatment. 

Source: Jazz Pharmaceuticals 

---

Partnering News 

Genentech, Repertoire in $765-M Autoimmune Disease Drug Pact 
Roche’s Genentech and Repertoire Immune Medicines, a Cambridge, Massachusetts-based bio/pharmaceutical company, have entered into a collaboration and license agreement to discover and develop T cell-targeted immune medicines to treat an undisclosed autoimmune disease, in a deal worth up to $765 million ($35 million upfront and $730 million in milestone payments).  

Under the agreement, Repertoire will deploy its Decode platform, which maps the immune synapse, to discover therapeutic targets, and Genentech will be responsible for preclinical and clinical development as well as the global commercialization of therapies that incorporate the target discovery work. Repertoire is eligible to receive $35 million upfront as well as up to $730 million in additional development, regulatory and commercial milestones, as well as tiered royalties. The Decode platform elucidates the entire immune synapse to provide an understanding of the interactions between T cell receptors and their cognate antigenic epitopes. Repertoire is developing T cell-targeted therapies for the treatment of cancer and autoimmune diseases.  

Source: Repertoire Immune Medicines 

---

Appointments 

Galapagos Appoints CEO of Subsidiary, Announces Search for CEO of Galapagos 
Galapagos, a Mechelen, Belgium-based bio/pharmaceutical company, has announced that in line with its planned separation into two independent entities, Henry Gosebruc, formerly President and Chief Executive Officer (CEO) at Neumora, a clinical-stage bio/pharmaceutical company, has been appointed as founding CEO of the Galapagos subsidiary, currently named XYZ SpinCo NV. SpinCo will separate from Galapagos’ current operations and initially be funded with approximately EUR 2.45 billion ($2.78 billion) in cash and cash equivalents.  

Additionally, Dr. Stoffels, currently Chair and CEO of Galapagos, has informed the company’s Board of Directors of his intent to retire from his role as CEO upon appointment of a successor and to remain as Non-Executive Chair of the Galapagos Board of Directors, thereby being able to continue to provide strategic guidance and support to the company, subject to his reappointment as Director at the company’s 2026 Annual General Meeting. The Board will search for a successor CEO, who will lead Galapagos into its next phase of growth as a focused cell-therapy company. The successor CEO is expected to be hired in the next 12 months (as reported on April 2025). 

Source: Galapagos 

---

Asahi Kasei Names Head of Healthcare Sector 
Asahi Kasei has appointed Ken Shinomiya, currently President of Asahi Kasei Life Science, as the Leader of its Healthcare Sector succeeding Richard Packer in that role.  Under Shinomiya, Asahi Kasei’s Healthcare Sector will further advance its portfolio and global presence of pharmaceuticals and life-science and critical-care products and services. 

Having served as Vice President of Strategy at ZOLL Medical Corporation from fiscal 2016 to fiscal 2017, Shinomiya became Head of the Bioprocess Division of Asahi Kasei Medical in April 2019 and President of Asahi Kasei Medical in April 2023. In April 2025, he was named President of Asahi Kasei Life Science, the successor company to the bioprocess business of Asahi Kasei Medical.  

Source: Asahi Kasei